Compare Novavax Inc (NVAX) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Invesco Preferred ETF — how do they compare? Novavax Inc trades at $7.94 (market cap $1.30B), while Invesco Preferred ETF trades at $10.64. The key difference: Novavax Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| NVAX | PGX | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | — |
52-Week High | $11.19 | $11.87 |
52-Week Low | $6.22 | $10.65 |
Enterprise Value | $879.40M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
PGX trades at $10.72 with a slight 0.28% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $11 across multiple levels. Recent corporate actions include scheduled dividends for mid-2026, but current financial ratios and income statements lack available data for fundamental assessment.
The outlook remains cautious due to bearish technical signals and limited fundamental visibility. Investment opportunities hinge on future financial disclosures and business developments, while risks include technical downtrend continuation and potential volatility from unresolved financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
